Today's Information

Provided by: OBI Pharma, Inc.
SEQ_NO 6 Date of announcement 2022/08/08 Time of announcement 16:33:44
Subject 
 Announcement that the cumulative reduction of
shareholding in major subsidiary, AP Biosciences, has
reached more than 10%
Date of events 2022/08/08 To which item it meets paragraph 51
Statement 
1.Name of major subsidiary:
  AP Biosciences, Inc. (hereinafter referred to as "AP Biosciences")
2.Cause of occurrence (reduce the percentage of
shareholding (or capital contribution to) or lose control ):
  Reduce the percentage of shareholding
3.Method of shareholding (or capital contribution) reduction
(Please specify the date, reason, method, reduction percentage,
volume, unit price, and total amount each time):
  The Company has listed AP Biosciences as one of major subsidiaries since
  March 2022. The method of shareholding reduction is specified as follows:
  (1)The date:2020/11/02 (the reference date of cash capital increase)
     The reason:Disproportionate investment in AP Biosciences' cash capital
     increase.
     The method:Cash capital increase
     Reduction percentage:From 67.00% to 58.99%
     Reduction volume, unit price, and total amount:Not applicable
  (2)The date:2021/02/22(the reference date of cash capital increase)
     The reason:Disproportionate investment in AP Biosciences' cash capital
     increase.
     The method:Cash capital increase
     Reduction percentage:From 58.99% to 54.62%
     Reduction volume, unit price, and total amount:Not applicable
  (3)The date: The Company resolved to forfeit the preemptive rights of AP
     Biosciences' cash capital increase on 2022/08/08, the reference date of
     cash capital increase will be 2022/10/04 tentatively.
     The reason:Disproportionate investment in AP Biosciences' cash capital
     increase
     The method:Cash capital increase
     Reduction percentage:From 54.62% to 41.12%
     Reduction volume, unit price, and total amount:Not applicable
4.Method of loss of control(Please specify the date,
 reason, and method):Not applicable
  After comprehensive consideration, as the Company is still the largest
  shareholder of AP Biosciences with more than half of the total number of
  directors under control, it is considered that the Company did not lose
  control of AP Biosciences.
5.Equity (or capital) recipient or counterparty
(please list separately for each transaction):
  (1)The reference date of cash capital increase: 2020/11/02
     Specific persons contacted as the Company disproportionately invest in
     AP Biosciences' cash capital increase:Hui Hong Investment Co. Ltd
  (2)The reference date of cash capital increase: 2021/02/22
     Specific persons contacted as the Company disproportionately invest in
     AP Biosciences' cash capital increase:Chia-Hung Lin
  (3)The reference date of cash capital increase: 2022/10/04 (tentatively)
     Specific persons contacted as the Company disproportionately invest in
     AP Biosciences' cash capital increase:Shareholders of the Company.
6.Relationship with counterparty (Please specify
 the relationship with counterparty each time):Not applicable
7.Gains (or losses) on disposal (Please specify the
 gains (or losses) on disposal each time.If there
is no gains (or losses), please fill in "NA"):Not applicable
8.Cumulative reduction of shareholding in major
subsidiaries so far (including the current transaction):Reduce 25.88%
9.Shareholding in major subsidiaries at present (after
 the current transaction):41.12%
10.Name of independent expert and his/her opinion on
reasonableness of pricing in each transaction: :Not applicable
11.Name of independent expert and his/her opinion on
the impact of reduction of shareholding or loss of control
on the rights of the TPEx listed company's shareholders:
   CPA Karin Lin of Chainye Accounting Firm.
   There's no impact on the rights of the Company's shareholders.
12.Any effect on the ongoing listing of the parent
company on TPEx:No effect.
13.Date of audit committee resolution:2022/08/08
14.Details of audit committee resolution:
   The Audit Committee approved the proposal unanimously with no changes.
15.Date of board of directors resolution:2022/08/08
16.Details of board of directors resolution:
   The Board of Directors approved the proposal unanimously with no changes.
17.Any other matters that need to be specified:Not applicable

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:53:08 UTC.